Metabolic Syndrome Risk Associated with Atypical Antipsychotic Medication: A Case Report

  • Julaeha Julaeha Department of Clinical and Community Pharmacy, Universitas 17 Agustus 1945 Jakarta, Indonesia
  • Umi Athiyah Department of Pharmacy Practice, Universitas Airlangga, Indonesia
  • Josephine P Ayuningtyas Department of Pharmacy, Menur National Mental Hospital, Indonesia
  • Verra Yuliana Department of Pharmacy, Menur National Mental Hospital, Indonesia
  • Andi Hermansyah Department of Pharmacy Practice, Universitas Airlangga, Indonesia

Abstract

People with schizophrenia are vulnerable group suffer from metabolic syndrome events. Atypical antipsychotics associated with weight gain, insulin resistance, and profile lipid abnormalities. The present case was 32-year-old man schizophrenia outpatient had experienced metabolic syndrome side effects. Metabolic syndrome characterized by central obesity, hyperglicemia, hypertriglyceridemia, low High Density Lipoprotein (HDL) cholesterol level, and several months feel an increase in appetite. Metabolic syndrome events might be associated with long-term atypical antipsychotics consuming and tobacco use. As pharmacists, We advised the patient to referral primary healthcare service for managing metabolic syndrome side effects. Pharmacists intervention through education and metabolic syndrome screening program have positive impacts on lifestyle modification such as decreasing number of cigarette consumption and caffeine intake, also increasing physical activity.


Keywords: Antipsychotics, Atypical antipsychotic, Metabolic syndrome, Pharmacist, Schizophrenia.

Keywords: Antipsychotics, Atypical antipsychotic, Metabolic syndrome, Pharmacist, Schizophrenia

Downloads

Download data is not yet available.

Author Biographies

Julaeha Julaeha, Department of Clinical and Community Pharmacy, Universitas 17 Agustus 1945 Jakarta, Indonesia

Department of Clinical and Community Pharmacy, Universitas 17 Agustus 1945 Jakarta, Indonesia

Umi Athiyah, Department of Pharmacy Practice, Universitas Airlangga, Indonesia

Department of Pharmacy Practice, Universitas Airlangga, Indonesia

Josephine P Ayuningtyas, Department of Pharmacy, Menur National Mental Hospital, Indonesia

Department of Pharmacy, Menur National Mental Hospital, Indonesia

Verra Yuliana, Department of Pharmacy, Menur National Mental Hospital, Indonesia

Department of Pharmacy, Menur National Mental Hospital, Indonesia

Andi Hermansyah, Department of Pharmacy Practice, Universitas Airlangga, Indonesia

Department of Pharmacy Practice, Universitas Airlangga, Indonesia

References

1. Lee AMH, Ng CG, Koh OH, Gill JS, Aziz SA. Metabolic Syndrome in First Episode Schizophrenia, Based on the National Mental Health Registry of Schizophrenia (NMHR) in a General Hospital in Malaysia: A 10-Year Retrospective Cohort Study. Int J Environ Res Public Health, 2018; 15(5):933.
2. World Health Organization. Management of physical health conditions in adult with severe mental disorder. WHO. 2018.
3. Mohamud, WNW, Ismail, AAS, Sharifuddin, A, Ismail, IS, Musa, KI, Kadir, KA, Kamaruddin, NA, Yaacob, NA, Mustafa, N, Ali, O, et al. Prevalence of metabolic syndrome and its risk factors in adult Malaysians: Results of a nationwide survey. Diabetes Res. Clin. Pract, 2011; 91:239–245.
4. De Hert, M, Schreurs, V, Vancampfort, D, Van Winkel, R. Metabolic syndrome in people with schizophrenia: A review. World Psychiatry, 2009; 8:15–22.
5. Von Hausswolff-Juhlin, Y, Bjartveit, M, Lindström, E, Jones, P. Schizophrenia and physical health problems. Acta Psychiatr. Scand, 2009; 119:15–21.
6. Newcomer, J.W. Metabolic syndrome and mental illness. Am. J. Manag. Care, 2007; 13 (Suppl. 7):S170–S177.
7. Panati D, Sudhakar TP, Swetha P, Sayeli VK. A comparative study on metabolic syndrome in patients with schizophrenia treated using first-generation and second-generation antipsychotics. Arch Ment Health, 2020; 21:4-11.
8. Panesar K. Schizophrenia: Managing symptom with antipsychotics, 2012; 37(11):Epub.
9. Julaeha J, Athiyah U, Hermansyah A. The prescription patterns of second-generation antipsychotics in schizophrenia outpatient setting. Journal of Basic and Clinical Physiology and Pharmacology, 2019; 30(6).
10. Church TJ, Hamer DA, Ulbrich TR. Assessment and management of atypical antipsychotic-induced metabolic abnormalities. US Pharm, 2010; 35(11):41-48.
11. Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, Correll CU. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatrica Scandinavica, 2015; 132(2):97-108.
12. Yalcin N, Celiker A and Sertac AK. Compliance in schizophrenia spectrum disorder: the role of clinical pharmacist. International Clinical Psychopharmacology, 2019; 34(6):298-304.
Statistics
345 Views | 210 Downloads
How to Cite
1.
Julaeha J, Athiyah U, Ayuningtyas JP, Yuliana V, Hermansyah A. Metabolic Syndrome Risk Associated with Atypical Antipsychotic Medication: A Case Report. JDDT [Internet]. 15Jan.2021 [cited 28Sep.2021];11(1):77-9. Available from: https://jddtonline.info/index.php/jddt/article/view/4680